284 related articles for article (PubMed ID: 33042258)
1. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
2. Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [
Grzmil M; Imobersteg S; Blanc A; Frank S; Schibli R; Béhé MP
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959437
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Actinium-225 Labeled Minigastrin Analogue [
Qin Y; Imobersteg S; Blanc A; Frank S; Schibli R; Béhé MP; Grzmil M
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33198403
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
6. Signaling Network Response to α-Particle-Targeted Therapy with the
Qin Y; Imobersteg S; Frank S; Blanc A; Chiorazzo T; Berger P; Schibli R; Béhé MP; Grzmil M
J Nucl Med; 2023 Jun; 64(6):873-879. PubMed ID: 36732057
[TBL] [Abstract][Full Text] [Related]
7. Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin
Grob NM; Schibli R; Béhé M; Mindt TL
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071914
[TBL] [Abstract][Full Text] [Related]
8. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT).
Grzmil M; Boersema P; Sharma A; Blanc A; Imobersteg S; Pruschy M; Picotti P; Schibli R; Behe M
J Hematol Oncol; 2022 Aug; 15(1):123. PubMed ID: 36045419
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
11. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
12. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
13. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging.
Aloj L; Caracò C; Panico M; Zannetti A; Del Vecchio S; Tesauro D; De Luca S; Arra C; Pedone C; Morelli G; Salvatore M
J Nucl Med; 2004 Mar; 45(3):485-94. PubMed ID: 15001692
[TBL] [Abstract][Full Text] [Related]
15. In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [
Rottenburger C; Hentschel M; Fürstner M; McDougall L; Kottoros D; Kaul F; Mansi R; Fani M; Vija AH; Schibli R; Geistlich S; Behe M; Christ ER; Wild D
EJNMMI Res; 2024 Apr; 14(1):37. PubMed ID: 38581480
[TBL] [Abstract][Full Text] [Related]
16. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
17. Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo.
Holzleitner N; Günther T; Beck R; Lapa C; Wester HJ
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558917
[TBL] [Abstract][Full Text] [Related]
18. An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.
Cho EH; Lim JC; Lee SY; Jung SH
J Pharmacol Sci; 2016 Jul; 131(3):209-14. PubMed ID: 27430985
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.
Bison SM; Pool SE; Koelewijn SJ; van der Graaf LM; Groen HC; Melis M; de Jong M
EJNMMI Res; 2014; 4():21. PubMed ID: 24995150
[TBL] [Abstract][Full Text] [Related]
20. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
